Adam Sonabend to join Northwestern
Adam Sonabend, MD, will join the Department of Neurological Surgery as Assistant Professor at Northwestern University Feinberg School of Medicine and will treat patients with brain tumors at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital, effective August 1. He is currently Assistant Professor of Neurological Surgery at Columbia University Medical Center and Director of the Translational Brain Tumor Lab at Herbert Irving Comprehensive Cancer Center.
Dr. Sonabend earned his medical degree at the National Autonomous University of Mexico, where he was awarded the Gabino Barreda Medal for the Highest Academic Achievement. He trained in neurosurgery at Columbia University, where he conducted research on the relationship between transcriptional regulation and the selection of genetic alternations during glioma progression and on drug delivery strategies for brain tumors. In 2015, he was one of only 16 physicians-scientists, and the only neurosurgeon in the U.S., to receive a prestigious NIH Early Independence Award.
Dr. Sonabend's primary clinical focus is the surgical management of tumors of the brain and skull base, including brain metastasis from other cancers, intraventricular tumors, gliomas such as oligodendrogliomas, ependymomas, astrocytomas and glioblastomas, CNS lymphoma, meningiomas, and craniopharyngiomas. He is also interested in trigeminal neuralgia and its surgical management. As a surgeon, he integrates techniques such as laser ablation, radiosurgery, convection-enhanced delivery, stereotaxic navigation, fluorescent microscopy, microsurgery, as well as awake and asleep brain mapping techniques with electrophysiology to achieve safe and effective resections.
His research focuses on topoisomerase II-mediated transcriptional regulation in gliomas, and personalized use of TOP2- targeting chemotherapy to treat malignant brain cancer. He is also investigating how the immune system shapes the genome of malignant gliomas, and its implications for immunotherapy for this disease. He has participated in the design and execution of several clinical trials and has been a temporary member of the Clinical Neuroimmunology and Brain Tumors (CNBT) study section at the NIH since 2016.